

**TOXICOLOGICAL PROFILE FOR  
1,3-DINITROBENZENE AND 1,3,5-TRINITROBENZENE**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  
Agency for Toxic Substances and Disease Registry

June 1995

**DISCLAIMER**

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

**UPDATE STATEMENT**

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry  
Division of Toxicology/Toxicology Information Branch  
1600 Clifton Road NE, E-29  
Atlanta, Georgia 30333



## FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and the Environmental Protection Agency (EPA) and in support of Department of Defense information needs. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, when known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are significant to protect public health will be identified by ATSDR and the EPA. The focus of the profiles is on health and toxicologic information; therefore, we have included this information in the beginning of the document.

Each profile must include the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects.
- (C) When appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that might present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). Section 211 of SARA also amended Title 10 of the U. S. Code, creating the Defense Environmental Restoration Program. Section 2704(a) of Title 10 of the U. S. Code directs the Secretary of Defense to notify the Secretary of Health and Human Services of not less than 25 of the most commonly found unregulated hazardous substances at defense facilities.

Section 2704(b) of Title 10 of the U. S. Code directs the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare a toxicological profile for each substance on the list provided by the Secretary of Defense under subsection (b).

**Foreword**

This profile reflects our assessment of all relevant toxicologic testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



David Satcher, M.D., Ph.D.  
Administrator  
Agency for Toxic Substances and  
Disease Registry

## CONTRIBUTORS

### CHEMICAL MANAGER(S)/AUTHOR(S):

Alfred Dorsey, D.V.M.  
ATSDR, Division of Toxicology, Atlanta, GA

Fernando Lladós, Ph.D.  
Research Triangle Institute, Research Triangle Park, NC

### THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Green Border Review. Green Border review assures consistency with ATSDR policy.
2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
4. Quality Assurance Review. The Quality Assurance Branch assures that consistency across profiles is maintained, identifies any significant problems in format or content, and establishes that Guidance has been followed.



**PEER REVIEW**

A peer review panel was assembled for 1,3-DNB and 1,3,5-TNB. The panel consisted of the following members:

1. Dr. Gordon Edwards, President, Toxicon Associates, Natick, Massachusetts;
2. Dr. William George, Professor, Department of Pharmacology, Tulane University, New Orleans, Louisiana; and
3. Dr. Lloyd Hastings, Research Associate\* Professor, Department of Environmental Health, University of Cincinnati, Cincinnati, Ohio.

These experts collectively have knowledge of 1,3-DNB's and 1,3,5-TNB's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.



## CONTENTS

FOREWORD .....	v
CONTRIBUTORS .....	vii
PEER REVIEW .....	ix
LIST OF FIGURES .....	xv
LIST OF TABLES .....	xvii
1. PUBLIC HEALTH STATEMENT .....	1
1.1 WHAT ARE 1,3-DNB and 1,3,5-TNB? .....	2
1.2 WHAT HAPPENS TO 1,3-DNB or 1,3,5-TNB WHEN IT ENTERS THE ENVIRONMENT? .....	2
1.3 HOW MIGHT I BE EXPOSED TO 1,3-DNB OR 1,3,5-TNB? .....	3
1.4 HOW CAN 1,3-DNB AND 1,3,5-TNB ENTER AND LEAVE MY BODY? .....	3
1.5 HOW CAN 1,3-DNB AND 1,3,5-TNB AFFECT MY HEALTH? .....	4
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 1,3-DNB OR 1,3,5-TNB? .....	5
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .....	5
1.8 WHERE CAN I GET MORE INFORMATION? .....	5
2. HEALTH EFFECTS .....	7
2.1 INTRODUCTION .....	7
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .....	7
2.2.1 Inhalation Exposure .....	9
2.2.1.1 Death .....	9
2.2.1.2 Systemic Effects .....	9
2.2.1.3 Immunological and Lymphoreticular Effects .....	11
2.2.1.4 Neurological Effects .....	11
2.2.1.5 Reproductive Effects .....	12
2.2.1.6 Developmental Effects .....	12
2.2.1.7 Genotoxic Effects .....	12
2.2.1.8 Cancer .....	12
2.2.2 Oral Exposure .....	12
2.2.2.1 Death .....	12
2.2.2.2 Systemic Effects .....	13
2.2.2.3 Immunological and Lymphoreticular Effects .....	27
2.2.2.4 Neurological Effects .....	27
2.2.2.5 Reproductive Effects .....	28
2.2.2.6 Developmental Effects .....	30
2.2.2.7 Genotoxic Effects .....	30
2.2.2.8 Cancer .....	30
2.2.3 Dermal Exposure .....	31
2.2.3.1 Death .....	31

2.2.3.2	Systemic Effects	31
2.2.3.3	Immunological and Lymphoreticular Effects	33
2.2.3.4	Neurological Effects	34
2.2.3.5	Reproductive Effects	34
2.2.3.6	Developmental Effects	34
2.2.3.7	Genotoxic Effects	34
2.2.3.8	Cancer	34
2.3	TOXICOKINETICS	34
2.3.1	Absorption	35
2.3.1.1	Inhalation Exposure	35
2.3.1.2	Oral Exposure	36
2.3.1.3	Dermal Exposure	36
2.3.2	Distribution	37
2.3.2.1	Inhalation Exposure	37
2.3.2.2	Oral Exposure	37
2.3.2.3	Dermal Exposure	38
2.3.2.4	Other Routes of Exposure	38
2.3.3	Metabolism	38
2.3.3.1	Inhalation Exposure	38
2.3.3.2	Oral Exposure	38
2.3.3.3	Dermal Exposure	39
2.3.3.4	Other Routes of Exposure	41
2.3.4	Excretion	41
2.3.4.1	Inhalation Exposure	41
2.3.4.2	Oral Exposure	42
2.3.4.3	Dermal Exposure	42
2.3.4.4	Other Routes of Exposure	42
2.3.5	Mechanisms of Action	43
2.4	RELEVANCE TO PUBLIC HEALTH	44
2.5	BIOMARKERS OF EXPOSURE AND EFFECT	56
2.5.1	Biomarkers Used to Identify or Quantify Exposure to 1,3-DNB and 1,3,5-TNB	57
2.5.2	Biomarkers Used to Characterize Effects Caused by 1,3-DNB and 1,3,5-TNB	57
2.6	INTERACTIONS WITH OTHER CHEMICALS	58
2.7	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	59
2.8	METHODS FOR REDUCING TOXIC EFFECTS	59
2.8.1	Reducing Peak Absorption Following Exposure	60
2.8.2	Reducing Body Burden	60
2.8.3	Interfering with the Mechanism of Action for Toxic Effects	60
2.9	ADEQUACY OF THE DATABASE	61
2.9.1	Existing Information on Health Effects of 1,3-DNB and 1,3,5-TNB	62
2.9.2	Identification of Data Needs	65
2.9.3	Ongoing Studies	71
3.	CHEMICAL AND PHYSICAL INFORMATION	73
3.1	CHEMICAL IDENTITY	73
3.2	PHYSICAL AND CHEMICAL PROPERTIES	73
4.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	77
4.1	PRODUCTION	77

4.2	IMPORT/EXPORT .....	79
4.3	USE .....	79
4.4	DISPOSAL .....	79
5.	POTENTIAL FOR HUMAN EXPOSURE .....	81
5.1	OVERVIEW .....	81
5.2	RELEASES TO THE ENVIRONMENT .....	83
5.2.1	Air .....	83
5.2.2	Water .....	83
5.2.3	Soil .....	85
5.3	ENVIRONMENTAL FATE .....	85
5.3.1	Transport and Partitioning .....	85
5.3.2	Transformation and Degradation .....	87
5.3.2.1	Air .....	87
5.3.2.2	Water .....	87
5.3.2.3	Sediment and Soil .....	88
5.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT .....	90
5.4.1	Air .....	90
5.4.2	Water .....	90
5.4.3	Sediment and Soil .....	91
5.4.4	Other Environmental Media .....	91
5.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE .....	91
5.6	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .....	92
5.7	ADEQUACY OF THE DATABASE .....	92
5.7.1	Identification of Data Needs .....	92
5.7.2	Ongoing Studies .....	96
6.	ANALYTICAL METHODS .....	97
6.1	BIOLOGICAL SAMPLES .....	97
6.2	ENVIRONMENTAL SAMPLES .....	100
6.3	ADEQUACY OF THE DATABASE .....	106
6.3.1	Identification of Data Needs .....	106
6.3.2	Ongoing Studies .....	108
7.	REGULATIONS AND ADVISORIES .....	109
8.	REFERENCES .....	119
9.	GLOSSARY .....	136
 APPENDICES		
A.	USER'S GUIDE .....	A-1
B.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS .....	B-1



**LIST OF FIGURES**

2-1	Levels of Significant Exposure to 1,3-DNB - Oral .....	21
2-2	Proposed Pathway of Metabolism of 1,3-DNB in Rats and Hamsters .....	40
2-3	Existing Information on Health Effects of 1,3-DNB .....	63
2-4	Existing Information on Health Effects of 1,3,5-TNB .....	64
5-1	Frequency of NPL Sites with 1,3-DNB and 1,3,5-TNB Contamination .....	82



**LIST OF TABLES**

2-1	Levels of Significant Exposure to 1,3-DNB - Oral .....	14
2-2	Genotoxicity of 1,3-DNB <i>In Vitro</i> .....	53
2-3	Genotoxicity of 1,3,5-TNB <i>In Vitro</i> .....	55
2-4	Ongoing Studies on 1,3-DNB and 1,3,5-TNB .....	72
3-1	Chemical Identity of 1,3-DNB and 1,3,5-TNB .....	74
3-2	Physical and Chemical Properties of 1,3-DNB and 1,3,5-TNB .....	75
4-1	Facilities that Manufacture or Process 1,3-DNB .....	78
5-1	Releases to the Environment from Facilities that Manufacture or Process 1,3-DNB .....	84
6-1	Analytical Methods for Determining 1,3-DNB and 1,3,5-TNB in Biological Samples .....	98
6-2	Analytical Methods for Determining 1,3-DNB and 1,3,5-TNB in Environmental Samples .....	102
7-1	Regulations and Guidelines Applicable to 1,3-DNB and 1,3,5-TNB .....	111